Menu
← Oncology Approval Tracker
FDA DECISION ·
Enhertu
fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable or metastatic NSCLC with an activating HER2 (ERBB2) mutation on an FDA-approved test after prior systemic therapy.
LAMPGEN ANALYSIS
Why it matters
This lung cancer action is based on activating HER2 mutations rather than breast cancer HER2 expression thresholds.
What research teams should watch
Verify the mutation report and prior systemic treatment. Document lung symptoms and escalation plans during follow-up.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Biomarker-selected advanced NSCLCPRIMARY RECORDS